Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms

Executive Summary

More Phase III data for AbbVie's selective JAK1 inhibitor upadacitinib appear to back a potential best-in-class claim but eyes remain on safety after a death from pulmonary embolism.


Related Content

Theravance Banks $100m As J&J Bets Big On IBD Drug
AbbVie's Upadacitinib Aces Another Arthritis Trial, But Safety Concerns Linger
AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say
Q&A: AbbVie VP Lin On Filling Humira's Big Shoes In Immunology
ACR Roundup: JAK Safety Shown Across Multiple Trials
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
JAK Inhibitors Have Dupixent In Their Sights For Atopic Dermatitis
Lilly/Incyte's JAK Inhibitor Baricitinib Poised For FDA Approval After All
AbbVie May Be Poised For An Oral RA Smack Down


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts